Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors (ENGAGE)
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FMC-242 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are:
Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses?
Participants will need to come to the clinic to have the following:
- Physical exams to see if there are any side effects
- Standard lab tests to observe blood counts and other values
- ECGs to measure heart signals
- Blood drawn to measure how the drugs are being metabolized
- Imaging such as CT scans to monitor if the cancer is growing or not
調査の概要
状態
条件
詳細な説明
This is a first-in-human, Phase 1/2, open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability, PK, and anti-tumor activity of FMC-242 monotherapy and in combination in participants with locally advanced or metastatic solid tumors. FMC-242 is in a new class of drugs called PI3Kα:RAS breakers. The combination escalation cohorts may enroll while the monotherapy portion is still determining MTD/recommended dose for expansion (RDE).
This study is being conducted in two phases:
Phase 1 Dose Escalation: to determine the MTD and/or preliminary RP2D(s) and dosing regimen of FMC-242 monotherapy and in combination.
Phase 2 Cohort Expansion: to evaluate the efficacy and safety of FMC-242 at the RP2D(s) as a monotherapy and in combination in disease-specific cohorts.
After consenting to participate, participants will complete screening assessments during a Screening Period. Eligible participants will receive FMC-242 orally, at approximately the same time each day.
Depending on the tumor type, participants in combination cohorts will also receive the addition of another cancer drug administered per the local prescribing information/investigational labeling.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Aaron (Ron) Weitzman, CMO, MD
- 電話番号:650-457-1005
- メール:clinicaltrials@frontiermeds.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Males and females of age ≥ 18 years at the time of signing the informed consent document.
- No known downstream mutations in the AKT or RAS pathway
- Measurable disease per RECIST v1.1.
- Documented disease progression on, or disease recurrence after at least 1 line of standard of care (SoC) systemic treatment, including approved targeted therapy for patients with actionable mutations, or, in the opinion of the Investigator, would not be able to tolerate SoC therapy, or refused SoC therapy.
- Eastern Cooperative Oncology Group performance status 0-1.
- Adequate hematological, renal, and hepatic function.
- In Phase 1 only, must be willing to provide an on treatment tumor biopsy provided it is safe and medically feasible.
- Women and men of child-bearing potential must agree to use highly effective contraceptive methods.
- Willing and able to adhere to the study visit schedule and other protocol requirements.
- Has an archival tissue for retrospective confirmatory testing, unless discussed with the study Medical Monitor.
Exclusion Criteria:
- Prior use of a PI3Kα:RAS breaker (e.g., BBO-10203, VVD-159642).
- Prior use of a RAS inhibitor (either pan-RASi or isoform-specific)
- Received any systemic anti-cancer therapy or investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
- Received radiation within 14 days prior to the first dose of study drug.
- Clinically significant toxicity resulting from prior cancer therapies that have not returned to baseline or ≤ Grade 1
- Known, uncontrolled central nervous system (CNS) metastases.
- History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
- Prior malignancy, requiring treatment or intervention, within the previous 3 years of study drug dosing, except for appropriately treated local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, which are allowed.
- Pregnant or breastfeeding.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:FMC-242 Monotherapy
FMC-242 alone |
PI3Kα:RAS breaker |
|
実験的:Combination Cohort A
FMC-242 in combination with trastuzumab |
PI3Kα:RAS breaker HER2 targeting agent
他の名前:
|
|
実験的:Combination Cohort B
FMC-242 in combination with fulvestrant |
PI3Kα:RAS breaker selective estrogen receptor degrader
他の名前:
|
|
実験的:Combination Cohort C
FMC-242 in combination with a Pan (K)RAS inhibitor |
PI3Kα:RAS breaker Pan (K)RAS inhibitor |
|
実験的:Combination Cohort D
FMC-242 in combination with FMC-376 |
PI3Kα:RAS breaker KRAS G12C inhibitor (experimental) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 1 and Phase 2: Adverse Events
時間枠:Approximately 24 months
|
Number and grade of adverse events (AEs) with FMC-242 alone and in each of the combinations using CTCAE v 6.0 |
Approximately 24 months
|
|
Phase 1 : Dose Limiting Toxicities
時間枠:Up to 21 or 28 days
|
Number of dose limiting toxicities (DLTs) with FMC-242 alone and in each of the combinations |
Up to 21 or 28 days
|
|
Phase 2: Overall Response Rate
時間枠:Approximately 24 months
|
Assess the overall response rate (ORR) using RECIST 1.1 in participants treated with FMC-242 alone and in each of the combinations |
Approximately 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 1: Assess anti-tumor activity
時間枠:Approximately 24 months
|
To assess preliminary anti-tumor activity of FMC-242 alone and in combinations using RECIST v1.1 |
Approximately 24 months
|
|
Phase 1: FMC-242 Maximum observed plasma concentration
時間枠:6 weeks
|
Measure the maximum observed plasma concentration (Cmax) for FMC-242 |
6 weeks
|
|
Phase 1: FMC-242 time to maximum observed plasma concentration
時間枠:6 weeks
|
Measure time to maximum observed plasma concentration (Tmax) for FMC-242 |
6 weeks
|
|
Phase 1: FMC-242 trough observed concentration
時間枠:6 weeks
|
Measure trough observed concentration (Cmin) for FMC-242 |
6 weeks
|
|
Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval
時間枠:6 weeks
|
Measure area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-t, AUCtau) for FMC-242 |
6 weeks
|
|
Phase 1: Terminal half-life
時間枠:6 weeks
|
Measure the terminal half-life (t1/2) for FMC-242 |
6 weeks
|
|
Phase 1: Apparent clearance
時間枠:6 weeks
|
Determine apparent the clearance (Cl/F) for FMC-242 |
6 weeks
|
|
Phase 1: Determine the volume of distribution
時間枠:6 weeks
|
Determine volume of distribution (Vd/F) for FMC-242 |
6 weeks
|
協力者と研究者
捜査官
- スタディディレクター:Aaron (Ron) Weitzman, MD、Frontier Medicines
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- FrontierMed
- 2026-528809-31-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Aggregate study data will be shared at the end of the study.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。